SecBot SecBot
PRESS-RELEASE ·Filed Mar 26, 2026

SGP

SpyGlass Pharma, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Investors should monitor upcoming milestones, including the initiation of the BIM-DRS first-in-human trial in H2 2026 and four-year follow-up data from the FIH trial in Q4 2026. The strong clinical data and extended cash runway reduce near-term dilution risk and support long-term value creation if Phase 3 trials succeed.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$22.61
T+0 close · Mar 26, 2026 · via day close
Latest settled
−12.65%
T+60 · $19.75
Vs SPY
−28.72%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 27 $22.61entry
  2. T+1 · 8mo ago +3.36%α +3.72% · $23.37
  3. T+5 · 8mo ago +0.18%α −3.69% · $22.65
  4. T+20 · 7mo ago +4.60%α −8.14% · $23.65
  5. T+60 · 5mo ago −12.65%α −28.72% · $19.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SpyGlass Pharma reported its Q4 and full-year 2025 financial results alongside key clinical and corporate updates, including the successful $172.5 million IPO in February 2026. The company highlighted positive 12-month Phase 1/2 data for its BIM-IOL System, showing sustained intraocular pressure control and elimination of eye drops in 97% of patients. Despite increasing R&D and G&A expenses, the IPO has extended its cash runway to fund operations through 2028.

Key Financial Metrics

EPS
$-5.72
Deal Value
$172.5M

Key Facts

  • Raised $172.5 million in gross proceeds from IPO completed on February 9, 2026.
  • 12-month Phase 1/2 trial data show 98% of patients on the 78-mcg dose of BIM-IOL System were free of IOP-lowering eye drops, with a 34% mean IOP reduction and no serious ocular adverse events.
  • Cash, cash equivalents, and short-term investments totaled $107.4 million as of December 31, 2025, with post-IPO cash expected to fund operations through 2028.
  • Net loss was $12.6 million for Q4 2025 ($5.72/share), up from $8.4 million ($4.58/share) in Q4 2024.
  • Phase 3 trials (SGP-005 and SGP-006) for BIM-IOL System are underway, with first patients randomized in January 2026.

Financial Impact

The $172.5 million IPO significantly strengthens the balance sheet and extends cash runway to 2028, enabling full funding of Phase 3 trials and a first-in-human trial for BIM-DRS. However, net losses increased to $39.9 million in 2025 from $29.2 million in 2024 due to higher R&D and G&A spending.

cashdilutionR&D expensenet loss

Risk Factors

  • Clinical trial delays or adverse results in ongoing Phase 3 studies could negatively impact valuation.
  • As a pre-revenue biopharma company, SpyGlass Pharma remains dependent on successful clinical development and regulatory approval.
  • Increased operating losses may continue as R&D and commercial preparation costs rise.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3263396

Track record

9 reports on SGP

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +33.66% at T+20 after the Oct 19, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 No price data
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $33.32 Now $32.24 −3.24% settles Dec 11
  3. Oct 19, 202628d ago 8-K Bullish 6/10 Entry $26.16 Now $32.24 +23.24% settles Nov 17
  4. Oct 19, 202628d ago Press Release Bullish 7/10 Entry $24.60 to $32.88 Now $32.24 +31.06% ▲ +33.66% +37.12% vs SPY
  5. Oct 1, 20266w ago 8-K Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
  6. Oct 1, 20266w ago Press Release Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
  7. May 14, 202626w ago 8-K Neutral 4/10 Entry $23.21 to $18.44 Now $32.24 +38.91% ▼ −20.55% −22.67% vs SPY
  8. Mar 26, 202633w ago Press Release Bullish 8/10 Viewing Entry $22.61 to $23.65 Now $32.24 +42.59% ▲ +4.60% −8.14% vs SPY
  9. Mar 9, 202636w ago Press Release Bullish 8/10 Entry $27.12 to $21.07 Now $32.24 +18.88% ▼ −22.31% −19.50% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens Wed (10h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026